T. Rowe Price Investment Management, Inc. Arcellx, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Arcellx, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 944,638 shares of ACLX stock, worth $83.6 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
944,638
Previous 1,173,791
19.52%
Holding current value
$83.6 Million
Previous $64.8 Million
21.77%
% of portfolio
0.05%
Previous 0.04%
Shares
5 transactions
Others Institutions Holding ACLX
# of Institutions
205Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$354 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$344 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$332 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$311 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$218 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.88B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...